EP0600915A1 - Composition a base de buis pour le traitement de l'infection par le vih (virus de l'immunodeficience humaine) - Google Patents
Composition a base de buis pour le traitement de l'infection par le vih (virus de l'immunodeficience humaine)Info
- Publication number
- EP0600915A1 EP0600915A1 EP92915740A EP92915740A EP0600915A1 EP 0600915 A1 EP0600915 A1 EP 0600915A1 EP 92915740 A EP92915740 A EP 92915740A EP 92915740 A EP92915740 A EP 92915740A EP 0600915 A1 EP0600915 A1 EP 0600915A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- composition
- aids
- treatment
- plant
- preventive
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
Definitions
- the subject of the invention is a composition based on boxwood for the treatment of acquired immuno-depression syndrome (S.I.D.A) as well as patients seropositive for this retrovirus as well as all the pathologies in which TNF (Tumor Necrosis
- Patent FR-A-2,425,241 describes a hair product for stopping hair loss.
- Patent FR-N "3.114 M describes a medicament based on extract or active bodies extracted from boxwood which strengthens the power of the heart muscle and has a stimulating action on the heart.
- -FR- A- 2,615,394 this patent describes the use of certain 17 ketosteroids, possibly with an immunomodulator and / or an antiviral agent, to manufacture a medicament for the treatment and prevention of retroviral infections.
- REPLACEMENT SHEET (4, 3-b) (3 r 4-f) indoles for the preparation of drugs useful for the treatment of AIDS.
- compositions based on Buxus Sempervirens capable of combating tuberculosis as well as the methods for obtaining them.
- the subject of the invention is the application of a plant from the buxaceous family for the preparation of a medicament intended for the preventive and / or curative treatment of AIDS or similar syndromes as well as the treatment of patients seropositive for this retrovirus.
- the subject of the invention is a composition for the treatment of immune deficiency by correcting the parameters currently used to define this pathology by the fact that it uses a plant from the buxaceous family.
- Another object of the invention is to combine an active principle intended for the treatment of AIDS, or of similar syndromes, and a composition containing a plant of the buxaceous family in the pure state or in combination with inert and pharmaceutically excipients. acceptable.
- the main species of buxaceous is boxwood: Buxus sempervirens.
- the part used is essentially the leaf of the plant.
- the part used is also the stem (wood), the root and the bark of the root.
- composition notably consists of steroidal alkaloids specific to the buxaceous family derived from cycloartol: cyclobuxine D, especially buxamine.
- cyclobuxine D especially buxamine.
- the subject of the invention is also the application of a plant from the buxaceous family for the preparation of a medicament intended for the treatment of conditions in which TNF intervenes.
- the dosage used is approximately 330 mg every 8 hours in powder form and administered in capsules.
- This powder is obtained by passing through a mixer, the size of the particles obtained is approximately 50 microns. The grinding is done intermittently to avoid any overheating likely to alter the active product (s). The powder is then put in capsules which are stored dry in sachets of 50 capsules.
- the toxic dose registered in the Codex in 1974 and 1979 would be more than 4 grams for the tincture and 10 g in decoction.
- the dosage chosen is therefore below the values likely to be toxic.
- This Codex listed plant is known for a number of toxic effects from a certain dose.
- Figure 1 is a schematic view showing the evolution of CD4.
- Figure 2 is a schematic view showing the evolution of CD3.
- Figure 3 is a schematic view showing the evolution of CD8.
- Figure 4 is a schematic view showing the evolution of lymphocytes.
- CPE cytopathic effect
- RT reverse transcriptase
- CPE cytopathogenic effect
- the product dissolved in N-methyl pyrrolidone is studied at different concentrations (0.015 to 50 ⁇ g / ml). Before infection, the cells are incubated with or without product for 1 hour at 37oC.
- test is carried out in duplicate: one part on infected cells, for determining the antiviral activity and the other part on uninfected cells, to determine the cytotoxicity of the product.
- the first series is infected with HIV (suspension of LAV-1-BRU virus Barré-Sinoussi et al., Science, 220, 868 (1983) containing approximately 200 to 300 TCID 50 ) while the other series receives 100 ⁇ l of medium RPMI [containing 10% fetal calf serum, 100 U / ml of penicillin, 100 ⁇ g / ml of streptomycin and 2 umoles / ml of glutamine (8 x 10 4 cells per ml)].
- medium RPMI containing 10% fetal calf serum, 100 U / ml of penicillin, 100 ⁇ g / ml of streptomycin and 2 umoles / ml of glutamine (8 x 10 4 cells per ml)].
- Cell viability is determined according to a modification of the technique described by R. PAUWELS et al., J. Virol. Meth., 20, 309-321 (1988).
- the wells, still containing the cells (infected or non-infected), receive 20 ⁇ l of a solution of MTT (4,5-dimethylthiazol-2-yl 2,5-diphenyl tetrazolium bromide) at 7 mg / ml in buffer isotonic phosphate.
- MTT 4,5-dimethylthiazol-2-yl 2,5-diphenyl tetrazolium bromide
- MTT 4,5-dimethylthiazol-2-yl 2,5-diphenyl tetrazolium bromide
- the infected cells are lysed at about 60-70% compared to the uninfected cells.
- the formula :
- DO treated and inf. Cells
- DO treated and non-inf. Cells
- DO untreated and inf. Cells
- the reverse transcriptase (RT) activity is proportional to the amount of acid-precipitable radioactivity.
- The% inhibition of viral production is calculated using the formula:
- the product defined above also exhibits anti TNF (umour Necrosis Factor) activity.
- TNF is a cofactor for the activation of the HIV virus, especially in chronically infected cells.
- the TNF production study was carried out on mononuclear cells from 4 healthy donors, isolated from peripheral blood on a Ficoll gradient. After washing, the cells are cultured in microtiter plates at the rate of 7.5 ⁇ 10 5 cells / well in 100 ⁇ l of medium.
- the cells are incubated with or without product (concentrations ranging from 1.5 to 50 ⁇ g / ml) for 30 minutes at 37 ° C. before stimulation with 10 ng / ml of Phorbol 12-Myristate 13-Acetate (PMA).
- PMA Phorbol 12-Myristate 13-Acetate
- the supernatants of the various cultures were removed for the assay of TNF.
- the activity is estimated by measuring the cytotoxicity of supernatants with respect to a line of murine fibroblasts sensitive to TNF ⁇ and ⁇ .
- the cytotoxicity is estimated by the cell viability measured by MTT and compared with the cytotoxicity obtained by a standard range of recombinant TNF a.
- This experiment reveals an activity that inhibits the production of TNF, the IC 50 of which is close to 10 ⁇ g / ml.
- the anti-TNF activity is particularly interesting and allows application to the treatment of diseases in the mechanism of which this factor intervenes. Examples may be cited in particular: septic shock, respiratory distress syndrome, asthma and other chronic respiratory diseases bone resorption diseases, graft-against-host reaction rejection of allograft, fever and myalgia linked to AIDS infections and AIDS-related cachexia, Crohn's disease, ulcerative colitis malaria and the cerebral form of malaria.
- V.I.H virus Human Immunodeficiency Virus
- AIDS demonstrated significantly better 6-month survival in patients treated with A.Z.T. (98%) compared to the placebo group (78%).
- This product therefore had marketing authorization (A.M.M) in 1987 under the name of Retrovir (registered trademark).
- Professor DOURNON reported on an exhaustive and prospective study of 365 patients suffering from AIDS or ARC-Syndrome of unfavorable results.
- the beneficial effect of A.Z.T. does not exceed 6 months. From this date, CD4 lymphocytes and the frequency of opportunistic infections return to their original value. Survival is similar to that of untreated patients and no longer changes the natural course of the disease.
- the present invention also relates to combinations consisting of an active principle known for its antiretrovirus activity and of a composition comprising a plant of the buxaceous family in the pure state or in the presence of pharmaceutically acceptable excipients.
Abstract
Description
Claims
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR9108790A FR2678835B1 (fr) | 1991-07-10 | 1991-07-10 | Composition a base de buis pour le traitement de l'infection par le vih (virus de l'immunodefiscience humaine). |
FR9108790 | 1991-07-10 | ||
PCT/FR1992/000629 WO1993000916A1 (fr) | 1991-07-10 | 1992-07-03 | Composition a base de buis pour le traitement de l'infection par le vih (virus de l'immunodeficience humaine) |
Publications (2)
Publication Number | Publication Date |
---|---|
EP0600915A1 true EP0600915A1 (fr) | 1994-06-15 |
EP0600915B1 EP0600915B1 (fr) | 1997-11-12 |
Family
ID=9415025
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP92915740A Expired - Lifetime EP0600915B1 (fr) | 1991-07-10 | 1992-07-03 | Composition a base de buis pour le traitement de l'infection par le vih (virus de l'immunodeficience humaine) |
Country Status (7)
Country | Link |
---|---|
EP (1) | EP0600915B1 (fr) |
AT (1) | ATE160091T1 (fr) |
AU (1) | AU2327692A (fr) |
DE (1) | DE69223152T2 (fr) |
ES (1) | ES2112324T3 (fr) |
FR (1) | FR2678835B1 (fr) |
WO (1) | WO1993000916A1 (fr) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2716805B1 (fr) * | 1994-03-04 | 1996-05-24 | Nice Sophia Antipolis Universi | Composition immunomodulatrice utile en particulier pour le traitement des infections provoquées par VIH. |
FR2769840A1 (fr) * | 1997-10-17 | 1999-04-23 | Pierre Dellamonica | Utilisation d'un extrait alcaloidique de buxus sempervirens pour la fabrication d'un medicament a activite anti-il 2 |
RU2494588C1 (ru) * | 2012-05-24 | 2013-10-10 | Государственное научное учреждение Всероссийский научно-исследовательский технологический институт ремонта и эксплуатации машинно-тракторного парка Российской академии сельскохозяйственных наук (ГНУ ГОСНИТИ Россельхозакадемия) | Лемех плуга |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB782469A (en) * | 1954-07-14 | 1957-09-04 | Merck & Co Inc | Anti-t.b. factor |
-
1991
- 1991-07-10 FR FR9108790A patent/FR2678835B1/fr not_active Expired - Fee Related
-
1992
- 1992-07-03 EP EP92915740A patent/EP0600915B1/fr not_active Expired - Lifetime
- 1992-07-03 AU AU23276/92A patent/AU2327692A/en not_active Abandoned
- 1992-07-03 ES ES92915740T patent/ES2112324T3/es not_active Expired - Lifetime
- 1992-07-03 WO PCT/FR1992/000629 patent/WO1993000916A1/fr active IP Right Grant
- 1992-07-03 DE DE69223152T patent/DE69223152T2/de not_active Expired - Fee Related
- 1992-07-03 AT AT92915740T patent/ATE160091T1/de not_active IP Right Cessation
Non-Patent Citations (1)
Title |
---|
See references of WO9300916A1 * |
Also Published As
Publication number | Publication date |
---|---|
DE69223152T2 (de) | 1998-06-18 |
ATE160091T1 (de) | 1997-11-15 |
WO1993000916A1 (fr) | 1993-01-21 |
FR2678835A1 (fr) | 1993-01-15 |
FR2678835B1 (fr) | 1995-05-24 |
DE69223152D1 (de) | 1997-12-18 |
EP0600915B1 (fr) | 1997-11-12 |
AU2327692A (en) | 1993-02-11 |
ES2112324T3 (es) | 1998-04-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2008215743B2 (en) | A composition for selective serotonin reuptake inhibition and process thereof | |
Siveen et al. | Augmentation of humoral and cell mediated immune responses by Thujone | |
CN1147766A (zh) | 治疗感染的药物 | |
AU4615897A (en) | Pharmaceutical compositions containing parthenium integrifolium or parts thereof or an extract or component thereof, the use of such plant material for preparing certain medicines, and a method of preparing an extract of parthenium integrifolium | |
JP2009510053A (ja) | 桂皮抽出物を有効成分として含む腸内菌叢改善及び免疫機能増進用組成物 | |
KR20160005728A (ko) | 박테리오파지 테라피 | |
KR20130062329A (ko) | 알로에 베라의 항바이러스 특성 및 후천성 면역 결핍 증후군(aids) 치료 | |
JP2002068988A (ja) | ウイルス感染抑制剤及びそれを含有する飲食品 | |
EP0600915B1 (fr) | Composition a base de buis pour le traitement de l'infection par le vih (virus de l'immunodeficience humaine) | |
JP2001505583A (ja) | 抗ウイルス活性を有するサルビア種の抽出物 | |
TWI359669B (fr) | ||
US11083764B1 (en) | Pharmaceutical composition based on plant raw materials | |
WO2020026951A1 (fr) | Agent contre le norovirus | |
JP4037450B2 (ja) | 免疫調節剤としての脂環式ジアミンの使用 | |
JP7033263B1 (ja) | 免疫機能亢進用組成物 | |
WO2007137389A1 (fr) | Utilisation de composants obtenus du margousier (azadirachta indica) pour le traitement du vih/sida | |
US20230057065A1 (en) | Compositions comprising natural extracts for stimulating the immune response | |
FR2462164A1 (fr) | Medicament contre les maladies infectieuses des voies urina ires et digestives a base d'un lysat bacterien provenant d'au moins une souche d'escherichia coli | |
ES2761429T3 (es) | Composición farmacéutica antiviral, que contiene un extracto de Juncus acutus | |
JP2003238438A (ja) | 外因子から生体を防御する組成物 | |
WO2010004525A1 (fr) | Compositions renfermant une association de propolis et d'un dérivé phénolique et leurs applications biologiques | |
WO2022099414A1 (fr) | Compositions comprenant des extraits naturels pour stimuler la réponse immunitaire | |
GB2622661A (en) | Composition | |
WO2024062228A1 (fr) | Composition comprenant de l'abutilon fruticosum, de l'acacia nubica, de l'acacia bussei et de la myrsine africana, procédés de préparation et utilisations thérapeutiques | |
CA2184699A1 (fr) | Composition immunomodulatrice utile en particulier pour le traitement des infections provoquees par vih |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 19940204 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU MC NL SE |
|
17Q | First examination report despatched |
Effective date: 19960320 |
|
GRAG | Despatch of communication of intention to grant |
Free format text: ORIGINAL CODE: EPIDOS AGRA |
|
GRAH | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOS IGRA |
|
GRAH | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOS IGRA |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU MC NL SE |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: NL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 19971112 Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 19971112 Ref country code: GB Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 19971112 Ref country code: DK Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 19971112 Ref country code: AT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 19971112 |
|
REF | Corresponds to: |
Ref document number: 160091 Country of ref document: AT Date of ref document: 19971115 Kind code of ref document: T |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
REF | Corresponds to: |
Ref document number: 69223152 Country of ref document: DE Date of ref document: 19971218 |
|
ITF | It: translation for a ep patent filed |
Owner name: CON LOR S.R.L. |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 19980212 |
|
NLV1 | Nl: lapsed or annulled due to failure to fulfill the requirements of art. 29p and 29m of the patents act | ||
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FG2A Ref document number: 2112324 Country of ref document: ES Kind code of ref document: T3 |
|
GBV | Gb: ep patent (uk) treated as always having been void in accordance with gb section 77(7)/1977 [no translation filed] |
Effective date: 19971112 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 19980703 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: ES Payment date: 19980722 Year of fee payment: 7 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 19980731 Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 19980731 Ref country code: BE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 19980731 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: DE Payment date: 19980902 Year of fee payment: 7 |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
26N | No opposition filed | ||
BERE | Be: lapsed |
Owner name: REBOUILLAT ALAIN Effective date: 19980731 Owner name: DELLAMONICA PIERRE Effective date: 19980731 Owner name: DURANT JACQUES Effective date: 19980731 Owner name: UNIVERSITE DE NICE-SOPHIA ANTIPOLIS Effective date: 19980731 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MC Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 19990131 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: ES Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 19990704 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: DE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20000503 |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FD2A Effective date: 20000810 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES;WARNING: LAPSES OF ITALIAN PATENTS WITH EFFECTIVE DATE BEFORE 2007 MAY HAVE OCCURRED AT ANY TIME BEFORE 2007. THE CORRECT EFFECTIVE DATE MAY BE DIFFERENT FROM THE ONE RECORDED. Effective date: 20050703 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: FR Payment date: 20050728 Year of fee payment: 14 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: ST Effective date: 20070330 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: FR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20060731 |